Lactoferrin in obese children and adolescents with nonalcoholic fatty liver disease

Effect of lactoferrin in obese children and adolescents with nonalcoholic fatty liver disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202302847529384

Enrollment

Registered

2023-02-06

Start date

2023-02-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine Paediatrics

Interventions

Treatment group with lactoferrin

none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Obese children and adolescents with ultrasonography proven NAFLD Age 6-18 years

Exclusion criteria

Exclusion criteria: other causes of liver disorders including viral hepatitis, autoimmune hepatitis, Wilson disease and hemochromatosis drug induced hepatotoxicity

Design outcomes

Primary

Measure	Time frame
measurement of liver enzymes	—

Secondary

Measure	Time frame
FBG, fasting insulin, total lipid profile, interleukin 6, interleukin 10, homocysteine	—

Countries

Egypt

Contacts

Public ContactWael El Feky

Professor of Cardiothoracic surgery

waelfeky@yahoo.com00201004332200

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026